Financial Data and Key Metrics Changes - Incyte reported total revenues of $4.2 billion for 2024, a 15% increase compared to 2023, continuing steady growth since 2020 [6][8] - Jakafi net sales reached $2.8 billion, growing 8% year-over-year, while Opzelura saw a significant growth of 50% to $508 million [7][16] - The company ended 2024 with $2.2 billion in cash and no debt, maintaining a strong financial position [8] Business Line Data and Key Metrics Changes - Jakafi's net product revenue in Q4 2024 was $773 million, an 11% increase year-over-year, with total patients increasing by 10% [12][34] - Opzelura's Q4 net product revenue was $162 million, up 48% year-over-year, driven by growth in atopic dermatitis and vitiligo [15][36] - The full-year net revenue for Opzelura was $508 million, reflecting a 50% increase compared to 2023 [16][36] Market Data and Key Metrics Changes - The U.S. market for Opzelura is expanding, with significant contributions from new patients and refills in both atopic dermatitis and vitiligo [7][15] - The company anticipates continued growth in both U.S. and international markets, particularly in Germany, France, Italy, and Spain for Opzelura [36][93] Company Strategy and Development Direction - Incyte plans to leverage its existing commercial infrastructure to support the launches of new products, including Niktimvo and ruxolitinib cream [11][31] - The company aims to deliver over 10 high-impact launches by 2030, with multiple pivotal data readouts expected in 2025 [22][31] - A focus on expanding its pipeline and increasing investment in late-stage development assets is evident, with plans for at least three Phase 3 studies in 2025 [18][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong financial position and robust pipeline, anticipating significant revenue contributions from upcoming product launches [9][11] - The company expects continued demand growth for Jakafi and Opzelura, despite potential pricing pressures from regulatory changes [40][41] - Management highlighted the importance of achieving statistical significance in upcoming clinical trials to ensure competitive positioning in the market [60][76] Other Important Information - The company completed a $2 billion share repurchase during 2024, reflecting confidence in its financial health [8] - A leadership change was announced, with Mohamed Issa taking over as Executive Vice President, Head of U.S. Oncology [20] Q&A Session Summary Question: Expectations for Opzelura's Phase 3 in prurigo nodularis - Management indicated that if the Phase 3 data is similar to Phase 2 results, it would be a significant addition for patients [50] Question: Guidance for Opzelura - The guidance reflects continued demand growth and potential contributions from pediatric indications and European markets [55][56] Question: Impact of IRA on patient out-of-pocket costs - Management noted that while there may be some savings, the benefits may take time to materialize in sales [64] Question: Phase 3 trials for povo in hidradenitis suppurativa - Management confirmed that they expect to disclose data through a press release and a call with the investment community [80] Question: Mutant CALR and JAK2V617F programs - Management expects to provide proof-of-concept data for both programs later this year, focusing on traditional endpoints and early evidence of reduction [86]

Core Insights - Incyte reported $1.18 billion in revenue for Q4 2024, a 16.3% year-over-year increase, with an EPS of $1.43 compared to $1.06 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.15 billion by 2.63%, while the EPS fell short of the consensus estimate of $1.53 by 6.54% [1] Revenue Breakdown - Product royalty revenues were $159.29 million, slightly below the average estimate of $161.69 million, reflecting a 6.5% year-over-year increase [4] - Net product revenues for Iclusig were $27.37 million, compared to the average estimate of $29.69 million, marking a 0.9% year-over-year change [4] - Net product revenues for Pemazyre reached $23.14 million, exceeding the average estimate of $19.08 million, with a year-over-year increase of 12.1% [4] - Net product revenues for Minjuvi/Monjuvi were $32.81 million, slightly below the estimate of $33.75 million, but showed a significant year-over-year increase of 264.8% [4] - Net product revenues for Opzelura were $161.60 million, surpassing the average estimate of $150.33 million, with a year-over-year increase of 47.9% [4] - Net product revenues for Jakafi were $773.11 million, exceeding the average estimate of $745.88 million, reflecting an 11.2% year-over-year increase [4] - Net product revenues for Zynyz were $1.37 million, above the average estimate of $0.96 million [4] - Total product revenues amounted to $1.02 billion, exceeding the average estimate of $999.96 million, with an 18.3% year-over-year increase [4] - Royalty revenues for Olumiant were $38.49 million, slightly below the estimate of $39.58 million, showing a 4.6% year-over-year decrease [4] - Royalty revenues for Tabrecta were $6.29 million, in line with the average estimate of $6.27 million, reflecting a 34.4% year-over-year increase [4] - Royalty revenues for Jakavi were $114.19 million, slightly below the estimate of $116.30 million, with a 9.9% year-over-year increase [4] - Royalty revenues for Pemazyre were $0.33 million, below the average estimate of $0.67 million [4] Stock Performance - Incyte's shares have returned +5.1% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Group 1 - Incyte reported quarterly earnings of $1.43 per share, missing the Zacks Consensus Estimate of $1.53 per share, but showing an increase from $1.06 per share a year ago, resulting in an earnings surprise of -6.54% [1] - The company posted revenues of $1.18 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.63%, compared to year-ago revenues of $1.01 billion [2] - Incyte shares have increased approximately 7.3% since the beginning of the year, outperforming the S&P 500's gain of 2.5% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.24 on revenues of $1.02 billion, and for the current fiscal year, it is $6.17 on revenues of $4.64 billion [7] - The Medical - Biomedical and Genetics industry, to which Incyte belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

2024 Fourth Quarter & Full-Year Financial and Corporate Update February 10th, 2025 Fourth Quarter & FY 2024 Earnings Call Agenda Ben Strain Head of Investor Relations Introduction Hervé Hoppenot Chief Executive Officer Key Highlights & Commercial Review Pablo Cagnoni R&D Update President, Head of Research & Development Christiana Stamoulis Chief Financial Officer Financial Review Available for Q&A Matteo Trotta General Manager, U.S. Dermatology Steven Stein Chief Medical Officer 2 Forward Looking Statements ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones Conference Call and Webcast Scheduled Today at 8:00 a.m. ET WILMINGTON, Del. – February 10, 2025 – Incyte (Nasdaq:INCY) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided full year 2025 financial guidance. "2024 was an important year for Incyte, with a 15% increase in total revenues, ...

Core Viewpoint - Incyte (INCY) is expected to report strong quarterly earnings with a projected EPS of $1.58, reflecting a 49.1% increase year-over-year, and revenues forecasted at $1.15 billion, indicating a 13.5% increase compared to the same period last year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 3.2% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts project 'Revenues- Product royalty revenues' to be $161.69 million, reflecting an 8.1% increase year-over-year [5]. - 'Net product revenues- Iclusig' are expected to reach $29.69 million, indicating a 9.4% year-over-year change [5]. - 'Revenues- Product revenues' are forecasted at $979.15 million, representing a 13.6% increase from the prior year [5]. Specific Product Revenue Forecasts - 'Net product revenues- Pemazyre' are estimated at $22.54 million, showing a 9.1% increase year-over-year [6]. - 'Net product revenues- Minjuvi/ Monjuvi' are projected at $33.75 million, reflecting a significant increase of 275.2% from the previous year [6]. - 'Net product revenues- Opzelura' are expected to be $147.91 million, indicating a 35.4% increase year-over-year [6]. - 'Net product revenues- Jakafi' are projected to reach $744.96 million, reflecting a 7.2% increase [7]. - 'Royalty revenues- Olumiant' are expected to be $39.58 million, indicating a slight decrease of 1.9% [7]. - 'Royalty revenues- Tabrecta' are forecasted at $6.27 million, reflecting a 34.1% increase [7]. - 'Royalty revenues- Jakavi' are estimated at $116.30 million, indicating an 11.9% increase year-over-year [8]. Stock Performance - Over the past month, Incyte shares have recorded a return of +1.3%, compared to the Zacks S&P 500 composite's +1.7% change, suggesting that INCY is likely to perform in line with the overall market [9].

Incyte Corporation (INCY) is scheduled to report fourth-quarter and full-year 2024 results on Feb. 10, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.15 billion, while the same for earnings is pinned at $1.58 per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the past year, shares of Incyte have rallied 27.1% against the industry’s decline of 9.9%.Image Source: Zacks Investment ResearchLet’s see how things migh ...

Shares of Incyte (INCY) have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame.The outperformance can be attributed to new drug approvals and recent pipeline progress. Lead drug Jakafi (ruxolitinib) also maintains momentum.At the recently held J.P. Morgan Healthcare Conference, management highlighted that 2025 will be a transformational year for INCY with four potential launches.INCY Outperforms Indu ...

Niktimvo Approval and Launch - Niktimvo, a first-in-class therapeutic agent, was approved by the FDA on August 14, 2024, for the treatment of chronic GVHD after failure of at least two prior lines of systemic therapy [1][26] - The approval was based on positive data from the global AGAVE-201 trial, which showed 75% of patients receiving 0.3 mg/kg every two weeks achieved a response at six months of treatment (N=79) [1] - Niktimvo is the first and only FDA-approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis in chronic GVHD [3][26] - The U.S. launch of Niktimvo is expected in early February 2025, with product available in 9 mg and 22 mg vial sizes [26] Chronic GVHD and Market Need - Chronic GVHD is a serious condition affecting approximately 17,000 patients in the U.S., with nearly 50% of patients requiring at least three lines of treatment [5] - The condition develops in approximately 42% of allogeneic stem cell transplant recipients, highlighting the significant unmet medical need [5] AGAVE-201 Trial Results - The AGAVE-201 trial evaluated axatilimab in 241 patients with recurrent or refractory chronic GVHD, showing durable responses across all organs studied and patient subgroups [6][26] - The trial's primary endpoint was the proportion of patients achieving an objective response by cycle 7 day 1, with secondary endpoints including duration of response and quality-of-life assessments [6] Commercialization and Partnerships - Incyte and Syndax are co-commercializing Niktimvo in the U.S., with Incyte holding exclusive commercialization rights outside the U.S. [29] - Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB in 2016, and entered into a co-development and co-commercialization agreement with Incyte in September 2021 [9] Pipeline and Future Development - Axatilimab is being studied in frontline combination trials for chronic GVHD, including a Phase 2 trial with ruxolitinib and a Phase 3 trial with steroids [10] - Additional studies are underway for idiopathic pulmonary fibrosis, indicating potential expansion of axatilimab's therapeutic applications [10] Patient Support and Access - IncyteCARES provides personalized patient support, including financial assistance and education, to eligible U.S. patients prescribed Niktimvo [4]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Incyte (INCY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Incyte is one of 1011 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is l ...